Saturday, December 3, 2022


Biotechnology News Magazine

Revolo Biotherapeutics Announces That the Last Patient in its Phase 2a Trial of ‘1104 in Eosinophilic Esophagitis has Completed the Study

Latest Posts

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hematologic cancers, including in combination with azacytidine for elderly patients with AML unable to tolerate the standard of care.

Acer Therapeutics Announces $1.5M Private Placement

The proceeds from the private placement will be used by Acer Therapeutics for working capital and general corporate purposes and, together with Acer’s existing cash and cash equivalents, are expected to be sufficient to fund the Company’s anticipated operating and capital requirements through the fourth quarter of 2022.

AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “The selection of ACI-35.030 for further development is a significant step for this collaboration. Early clinical testing showed that ACI-35.030 was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and enriched paired helical filaments (ePHF) species, both of which are closely implicated in Alzheimer’s disease (AD).

TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors

The planned clinical trial is to evaluate TransCode’s lead therapeutic candidate, TTX-MC138, in cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode Therapeutics believes that TTX-MC138 could be used as a treatment for many of these cancers.

Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that the last patient has completed a Phase 2a proof of concept clinical study investigating its immune-resetting molecule, ‘1104, for the treatment of patients with eosinophilic esophagitis (EoE).

“The last patient out marks a key milestone in our Phase 2a trial in EoE, and we are looking forward to announcing topline data early next year,” said Jonathan Rigby, Group Chief Executive Officer of Revolo Biotherapeutics. “’1104 has the unique ability to reset the immune system ahead of the inflammatory cascade, providing a potentially promising new treatment option for patients without causing immunosuppression. ‘1104 stands out from other drug products that treat allergic disease by its broad effect in reducing a spectrum of key inflammatory cytokines and reduction of inflammatory immune cells, such as eosinophils, mast cells, neutrophils and lymphocytes. We are confident that the data in early 2023 will support its potential to have an improvement in symptomatic and physiologic response for EoE patients.”

Evan Dellon, M.D., MPH, Gastroenterologist, Professor of Medicine and Adjunct Professor of Epidemiology at the University of North Carolina Chapel Hill, and Principal Investigator for the clinical trial, added, “Despite the approval of the first treatment for EoE patients earlier this year, many are still very much in need of an effective and safe option to treat this complex and life-changing disease. Data from this study will provide insight into the safety and efficacy of ‘1104 in patients with EoE and, if positive, will inform the design of future late-stage studies. In the interest of patients, I am eager to see the data from this novel drug product.”

The Phase 2a, randomized, double-blind, placebo-controlled trial (NCT05084963) is designed to evaluate the safety and efficacy of ‘1104 in adults with EoE. Top line data is expected in early 2023.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine